Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.70 |
| ▸ | MAP3K8 | P41279 | 16/20 | 0.67 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.63 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.63 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.63 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.61 |
| ▸ | PRKCG | P05129 | 1/20 | 0.61 |
| ▸ | PRKCB | P05771 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | PRKCA | P17252 | 1/20 | 0.61 |
| ▸ | PRKCH | P24723 | 1/20 | 0.61 |
| ▸ | PRKCI | P41743 | 1/20 | 0.61 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.61 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.61 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.61 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.61 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4772668 | 0.92 | SRC (0.65) | EGFRERBB2MAP3K8MAPK13MAPK12 | |
| SCHEMBL4774213 | 0.91 | EGFR (0.58) | EGFRERBB2MAP3K8MAPK13MAPK12 | |
| SCHEMBL4775921 | 0.89 | SRC (0.64) | EGFRERBB2MAP3K8MAPK13MAPK12 | |
| SCHEMBL4774191 | 0.89 | EGFR (0.55) | EGFRERBB2MAP3K8MAPK13MAPK12 | |
| SCHEMBL4771773 | 0.89 | EGFR (0.67) | EGFRERBB2MAP3K8MAPK13MAPK12 | |
| SCHEMBL4767089 | 0.86 | EGFR (0.66) | EGFRERBB2MAP3K8MAPK13MAPK12 | |
| SCHEMBL4769767 | 0.85 | SRC (0.63) | EGFRERBB2MAP3K8MAPK13MAPK12 | |
| SCHEMBL14924281 | 0.85 | EGFR (0.75) | EGFRERBB2MAP3K8SRC | |
| SCHEMBL1891925 | 0.84 | MAP3K8 (0.73) | EGFRERBB2MAP3K8MAPK13MAPK12 | |
| SCHEMBL4960601 | 0.84 | EGFR (0.67) | EGFRERBB2MAP3K8MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432279-B2 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2008-10-07 | — | — | US | disclosed |
| CN-101223170-A | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of TPL2 kinase and methods of making and using the same | WYETH CORP (US) | 2008-07-16 | — | — | CN | disclosed |
| EP-1881981-A1 | 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | Wyeth (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124944-A1 | 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-1171440-B1 | SUBSTITUTED-3-CYANO-[1.7],[1.5], AND [1.8]-NAPHTHYRIDINE INHIBITORS OF TYROSINE KINASES | WYETH CORP (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6548496-B2 | Anticancer agents | AMERICAN CYANAMID COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-20020165229-A1 | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases | AMERICAN CYANAMID COMPANY | 2002-11-07 | — | — | US | disclosed |
| US-6355636-B1 | ENZYME INHIBITORS | AMERICAN CYANAMID COMPANY | 2002-03-12 | — | — | US | disclosed |
| EP-1171440-A1 | SUBSTITUTED-3-CYANO-[1.7],[1.5], AND [1.8]-NAPHTHYRIDINE INHIBITORS OF TYROSINE KINASES | American Cyanamid Company (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000066583-A1 | SUBSTITUTED 3-CYANO-[1.7], [1.5], AND [1.8]-NAPHTHYRIDINE INHIBITORS OF TYROSINE KINASES | AMERICAN CYANAMID COMPANY (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CNKSR1, DTYMK | EGFR 2871/4885ERBB2 1101/4885MAP3K8 99/4885 |
| US-20020165229-A1 | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases | ABL1, ROS1, ALK | EGFR 14/4885ERBB2 4/4885MAP3K8 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.